相关临床试验
24
10 进行中
药物批准
0
批准总数
监管机构
0
监管机构数
成立时间
N/A
进行中（未招募）
3
12.5%
已完成
9
37.5%
尚未招募
7
29.2%
招募中
4
16.7%
Unknown
1
4.2%
暂无批准数据
- DiaMedica Therapeutics reported positive interim Phase 2 results for DM199 (rinvecalinase alfa) in treating preeclampsia, showing statistically significant reductions in both systolic and diastolic blood pressure. - The highest dose cohort achieved substantial mean reductions of 35 mmHg in systolic blood pressure and 15 mmHg in diastolic blood pressure at 5 minutes post-infusion. - DM199 demonstrated no placental transfer and was generally well-tolerated with only mild adverse events, addressing a key safety concern in preeclampsia treatment development. - The drug also produced a 13.2% reduction in uterine artery pulsatility index, indicating improved placental perfusion that could support fetal growth and disease modification.
- Stellenbosch University initiates a clinical trial for DM199, a novel drug targeting the root cause of preeclampsia, a severe pregnancy complication. - DM199, a synthetic form of tissue-kallikrein-1, aims to improve blood vessel health by addressing endothelial dysfunction, unlike current treatments focused on managing blood pressure. - The trial employs a phased approach, starting with low doses to ensure safety for both the mother and the unborn child, addressing a critical gap in maternal healthcare. - This study marks a significant advancement, offering a potential targeted treatment for preeclampsia, which affects 5% of pregnancies and results in numerous maternal and fetal deaths.
